Dedifferentiated chondrosarcoma is an aggressive histologic subtype that warrants a specific treatment strategy, particularly in patients aged 40 or older or in those who cannot tolerate high-dose methotrexate.
This protocol addresses patients with dedifferentiated chondrosarcoma who are aged 40 years or older, or who have methotrexate intolerance. In this population, regimens formulated without methotrexate may still be effective, and the chemotherapy approach is individualised according to performance status, cardiac and renal function, and other co-morbidities.
Management is built around surgical intervention — with complete excision as the primary objective — combined with consideration of systemic chemotherapy in the neoadjuvant and/or adjuvant setting.
DOI: 10.1038/s41416-024-02868-4
In dedifferentiated chondrosarcoma, complete excision is recommended if feasible.
Amputation reduces the risk of local recurrence if wide margins cannot be achieved but there is a high risk of metastasis.
Although the role of chemotherapy in dedifferentiated chondrosarcoma is not well defined, osteosarcoma chemotherapy protocols can be considered as neo-adjuvant and or adjuvant therapy although survival is unfortunately poor.
For patients over 40 years and those who cannot tolerate HDMTX, regimens without methotrexate may still be effective.
AP alone is considered suitable therapy, although doses are not standardised and may vary according to performance status, cardiac and renal function and other co-morbidities.
View source ↗